Prostate-specific membrane antigen-directed therapy for metastatic castration-resistant prostate cancer Journal Article
| Authors: | Teo, M. Y.; Morris, M. J. |
| Article Title: | Prostate-specific membrane antigen-directed therapy for metastatic castration-resistant prostate cancer |
| Abstract: | Prostate-specific membrane antigen (PSMA) is highly expressed on both benign and malignant prostatic tissue. Prostate-specific membrane antigen-directed therapy is conceptually promising, with a potential to additionally serve as a theranostic model in management of advanced prostate cancer. To date, various approaches have been devised and tested, including radiolabeled PSMA antibodies and inhibitor and antibody-drug conjugates. However, development and progress have faced challenges in determining the optimal combination of payload, PSMA-binding moiety, and linker technology. We review the available clinical data to date in PSMA-directed therapies and discuss the challenges faced. © 2016 Wolters Kluwer Health, Inc. |
| Keywords: | prostate cancer; therapy; psma |
| Journal Title: | The Cancer Journal |
| Volume: | 22 |
| Issue: | 5 |
| ISSN: | 1528-9117 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2016-09-01 |
| Start Page: | 347 |
| End Page: | 352 |
| Language: | English |
| DOI: | 10.1097/ppo.0000000000000221 |
| PROVIDER: | scopus |
| PUBMED: | 27749329 |
| PMCID: | PMC5468166 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 2 November 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work